HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1- acetyl- 5- (2- (4- chlorophenoxy)phenylamino)- 2,3,4,5- tetrahydrobenzo(b)azepine

inhibits 17beta-hydroxysteroid dehydrogenase type 3; structure in first source

Also Known As:

STX2171

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - 1-acetyl-5-(2-(4-chlorophenoxy)phenylamino)-2,3,4,5-tetrahydrobenzo(b)azepine: 1

Experts

1.	Day, Joanna M: 1 article (02/2013)
2.	Foster, Paul A: 1 article (02/2013)
3.	Hargrave, Jonathan D: 1 article (02/2013)
4.	Potter, Barry V L: 1 article (02/2013)
5.	Purohit, Atul: 1 article (02/2013)
6.	Reed, Michael J: 1 article (02/2013)
7.	Schmidlin, Fabien: 1 article (02/2013)
8.	Sharland, Christopher M: 1 article (02/2013)
9.	Tutill, Helena J: 1 article (02/2013)
10.	Vicker, Nigel: 1 article (02/2013)

Related Diseases

1.

Prostatic Neoplasms (Prostate Cancer)

02/01/2013 - "STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model."
02/01/2013 - "In conclusion, STX2171 and STX1383 significantly lower plasma testosterone levels and inhibit androgen-dependent tumour growth in vivo, indicating that 17β-HSD3 inhibitors may have application in the treatment of hormone-dependent prostate cancer."

Related Drugs and Biologics

1.	Testosterone (Sustanon)
2.	Oxidoreductases (Dehydrogenase)
3.	Hormones (Hormone)
4.	Androgens